Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Don't miss the chance to present your research and join us in advancing oncology. Merit Travel Grants available. Keep up to date with practice-changing publications in ovarian cancer, HCC, advanced breast cancer, and join the discussion with key opinion leaders. The resources for this webinar include expert insights from the latest ESMO Living Guidelines applied to real clinical scenarios.
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease. Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management.
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication. Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care. Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection.
Additional evidence on time-limited venetoclaxβanti-CD20 antibody in first line is included. It is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling used for PET imaging. Treatment of gastrointestinal GI cancers is catching up with other areas of oncology and offering patients better prospects for survival and quality of life, but a significant uptick in early-onset cases is raising new questions about effective prevention, diagnosis and treatment.
Cross-border tumour boards of cancer specialists from different European countries meeting virtually to review the management of individual patients with complex rare gynaecological cancers from across Europe resulted in new treatment recommendations and increased access to clinical trials, according to results from a six-year study that will be presented at the ESMO Gynaecological Cancers Congress The European Society for Medical Oncology is pleased to announce the ESMO Gastrointestinal Cancers Congress , the scientific congress entirely dedicated to the presentation of advances and discussions around the prevention, diagnosis and management of malignancies of the gastrointestinal tract.
